GSK pushes more data for shingles vaccine, but no filing yet
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's shingles vaccine continues to demonstrate strong efficacy in all ages in Phase III trials but the company doesn't plan to file the product just yet.